Onkos Surgical Announces Definitive Agreement to Acquire JTS Expandable Prosthesis

The company is expanding its musculoskeletal oncology portfolio with device for treating pediatric bone cancer

PARSIPPANY, NJ, June 14, 2022 /OrthoSpineNews/ — Onkos Surgical, Inc., a rapidly growing, leading innovator of solutions for musculoskeletal oncology and complex orthopedic conditions, today announced that it has entered into a definitive agreement with Stryker to acquire the Juvenile Tumor System (JTS ). The system provides limb stabilization and growth in pediatric patients with bone cancers, severe arthropathies, severe trauma, revisions, oncology and malignancies.

Onkos is a MedTech company specializing in the development of solutions for surgeons specializing in musculoskeletal oncology and other complex orthopedic conditions.

The JTS is a device that allows non-invasive lengthening of the post-operative implant over time in a clinical setting. The design eliminates the need for multiple lengthening, anesthesia or sedation surgeries, and therefore helps reduce the risk of complications and costs associated with limb reconstruction surgery.

“This is an important day for Onkos Surgical and the musculoskeletal oncology community,” said Patrick Treacy, co-founder and CEO. “Our ‘Why’ has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and difficult procedures, and the JTS expandable prosthesis is a solution in service of this mission. We are committed to being good stewards of technology. We are proud to partner with this community of dedicated surgeons and excited to create a bright future for technology as we continue this meaningful work for pediatric patients with musculoskeletal cancer.

About Onkos Surgical
Onkos Surgical is a leader in innovative solutions for musculoskeletal oncology and complex orthopedic pathologies. With our precision orthopedic solutions, surgeons are better informed of patient-specific clinical challenges and are able to plan and implement a more precise reconstruction. Our personalized approach supports improving patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D anatomical modeling and printing, implant design, and workflow optimization . More than 350 of the leading academic medical institutions in the United States choose Onkos Surgical Precision Orthopedics. For more information about Onkos Surgical and its products and services, please visit www.onkossurgical.com.

Forward-looking statements
Certain statements made in this release that are not statements of historical or current fact are forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of company may differ materially from historical results or any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “future”, “believes”, “expects”, “may”, “will”, “should”, “potential”, “estimates”. , ‘intends’, ‘plans’ or ‘plans’ or the negative form of these terms or any other comparable terminology.

Forward-looking statements are based on management’s current beliefs, assumptions and expectations, but are subject to known and unknown risks and uncertainties, including, without limitation, market trends and demand, disruptions supply chain and other potential effects of the continuing COVID-19 pandemic. Although management believes that the expectations reflected in the forward-looking statements are reasonable, the forward-looking statements are not and should not be considered guarantees of future performance or results. The forward-looking statements included are made only as of the date of this release. The Company undertakes no obligation to update any information or forward-looking statements contained herein, except for any information required to be disclosed by law.

Media contacts:
Sean Curry
SVP, Commercial Operations
Onkos Surgical, Inc.

SOURCE Onkos Surgery

Comments are closed.